QURE ALERT: FDA Reportedly Accuses uniQure of Pushing "Distorted" and "Manipulated" Data For "Failed" AMT-130 Drug Amid Pending Securities Class Action - Hagens Berman
PR Newswire —
QURE Investors with Losses Encouraged to Contact Hagens Berman SAN FRANCISCO, March 12, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman is updating its investigation into uniQure N.V. (NASDAQ: QURE) following an unprecedented public rebuke of the company by federal...